Mind Medicine (MindMed) I... (MNMD)
NASDAQ: MNMD
· Real-Time Price · USD
9.46
-0.26 (-2.67%)
At close: Aug 15, 2025, 10:03 AM
-2.67% (1D)
| Bid | 6.97 |
| Market Cap | 715.11M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -114.52M |
| EPS (ttm) | -1.34 |
| PE Ratio (ttm) | -7.06 |
| Forward PE | -5.32 |
| Analyst | Buy |
| Ask | 9.48 |
| Volume | 219,797 |
| Avg. Volume (20D) | 1,274,475 |
| Open | 9.74 |
| Previous Close | 9.72 |
| Day's Range | 9.42 - 9.75 |
| 52-Week Range | 4.70 - 10.49 |
| Beta | 2.94 |
About MNMD
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol MNMD
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for MNMD stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts3 weeks ago
+12.05%
Shares of psychedelic companies are trading higher...
Unlock content with
Pro Subscription
1 month ago
+7.52%
Shares of psychedelic companies are trading higher following a report suggesting that the US Department of Health and Human Services Secretary Robert F. Kennedy Jr said the agency is committed to expanding research on the benefits of psychedelic therapy and is working with the FDA head to provide legal access for military veterans within 12 months.
2 weeks ago · seekingalpha.com
Mind Medicine (MindMed) Inc. (MNMD) Q2 2025 Earnings Call TranscriptMind Medicine (MindMed) Inc. (NASDAQ:MNMD ) Q2 2025 Earnings Conference Call July 31, 2025 4:30 PM ET Company Participants Brandi L. Roberts - Chief Financial Officer Daniel Rollings Karlin - Chief Me...
3 weeks ago · businesswire.com
MindMed to Report Second Quarter 2025 Financial Results on July 31, 2025NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain ...
